Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%
Executive Summary
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
You may also be interested in...
Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
With Irish Tax Assessment Upheld, Perrigo Plumbs US-Ireland Pact To Lower Debt
With both Ireland and US imposing tax assessments on same revenues – sales by Elan – tax agency officials from the countries will, at the request of Perrigo, negotiate whether both or one will demand payment and whether the amount will be lowered.
Perrigo Oral Care Targets North American Value Tier With High Ridge Brands Buy
REACH and Dr. Fresh, as well as Firefly kids’ toothbrushes and mouth rinses featuring popular comic book and cartoon characters, will join Perrigo’s Ranir division under the $113m cash deal, which is subject to federal bankruptcy court approval but expected to close in the 2020 first quarter.